|Bid||0.00 x 1100|
|Ask||0.00 x 800|
|Day's Range||17.48 - 18.26|
|52 Week Range||9.25 - 25.46|
|Beta (5Y Monthly)||1.17|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 01, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||27.33|
Omeros Corporation (Nasdaq: OMER) and Quantum Leap Healthcare Collaborative announced that dosing of patients with narsoplimab in the I-SPY COVID-19 Trial began earlier this month. The I-SPY COVID-19 Trial is an adaptive platform trial sponsored by Quantum Leap Healthcare Collaborative. The goal of the trial is to screen rapidly, in parallel, multiple promising agents in order to identify drugs that will have a high impact on reducing mortality and avoid or reduce the duration of mechanical ventilation for critically ill COVID-19 patients.
Omeros (OMER) delivered earnings and revenue surprises of 15.63% and -41.76%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Omeros (NASDAQ:OMER) fell in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share decreased 3.45% over the past year to ($0.60), which beat the estimate of ($0.64). Revenue of $10,632,000 decreased by 68.18% from the same period last year, which missed the estimate of $14,910,000. Guidance Earnings guidance hasn't been issued by the company for now. Omeros hasn't issued any revenue guidance for the time being. Conference Call Details Date: Mar 01, 2021 View more earnings on OMER Time: 04:30 PM ET Webcast URL: https://edge.media-server.com/mmc/p/zwyuoz5o Recent Stock Performance Company's 52-week high was at $25.46 52-week low: $8.50 Price action over last quarter: Up 75.18% Company Profile Omeros Corp is a United States-based biopharmaceutical company. Its goal is to research, develop, and commercialize small-molecule and protein therapeutics targeting inflammation, coagulopathies, and disorders of the central nervous system. The company owns Omidria (phenylephrine and ketorolac injection), approved by the U.S. Food and Drug Administration and launched in the U.S. for use during cataract surgery and intraocular lens replacement. Its product pipeline is focused on complement-associated thrombotic microangiopathies; complement-mediated glomerulonephropathies; Huntington's disease and cognitive impairment; and addictive and compulsive disorders. See more from BenzingaClick here for options trades from BenzingaEarnings Scheduled For March 1, 2021© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.